INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.33) by 26.15 percent. This is a 60 percent increase over losses of $(0.60) per share from the same period last year.
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.33) by 26.15 percent. This is a 60 percent increase over losses of $(0.60) per share from the same period last year.
Comments